Last reviewed · How we verify
Felodipine add Metoprolol
Felodipine and metoprolol together reduce blood pressure by relaxing blood vessels (felodipine) and slowing heart rate (metoprolol).
Felodipine and metoprolol together reduce blood pressure by relaxing blood vessels (felodipine) and slowing heart rate (metoprolol). Used for Hypertension, Angina pectoris.
At a glance
| Generic name | Felodipine add Metoprolol |
|---|---|
| Also known as | Plendil, Betaloc |
| Sponsor | LanZhou University |
| Drug class | Calcium channel blocker + Beta-blocker combination |
| Target | L-type calcium channels (felodipine); Beta-1 adrenergic receptor (metoprolol) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Felodipine is a dihydropyridine calcium channel blocker that inhibits L-type calcium channels in vascular smooth muscle, causing vasodilation. Metoprolol is a selective beta-1 adrenergic receptor antagonist that reduces heart rate and cardiac contractility. Combined, they provide complementary antihypertensive effects through different mechanisms.
Approved indications
- Hypertension
- Angina pectoris
Common side effects
- Peripheral edema
- Headache
- Dizziness
- Fatigue
- Bradycardia
- Flushing
Key clinical trials
- Combined Antihypertensive Therapy and Sexual Dysfunction (PHASE4)
- Efficacy and Safety of Metoprolol Succinate Prolonged-Release Tablet in Patients With Mild to Moderate Hypertension (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Felodipine add Metoprolol CI brief — competitive landscape report
- Felodipine add Metoprolol updates RSS · CI watch RSS
- LanZhou University portfolio CI